BIAFW — bioAffinity Technologies Inc. Warrant
NASDAQ
$0.08
-$0.04 (-35.54%)
bioAffinity Technologies Inc. Warrant (BIAFW) common stock listed on NASDAQ. It is led by Maria Zannes J.D., based in 3300 Nacogdoches Road, San Antonio, TX, United States, 78217, with about 57 employees. bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Latest reported BIAFW revenue for 2025-09-30 was $1.4M. Net income was -$5.1M. Revenue was up 13.9% from 2025-06-30 to 2025-09-30.
Use this BIAFW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BIAFW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BIAFW SEC filings page. Lician reads the product cache first so this HTML stays unique to bioAffinity Technologies Inc. Warrant even when a live quote feed is slow.
About bioAffinity Technologies Inc. Warrant
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
BIAFW Key Statistics
Market Cap
$0.00M
Volume
1,104
Previous Close
$0.12
Day Range
$0.08 – $0.08
EPS
-$0.75
Revenue
$9.36M
Net Income
-$9.04M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+18.5%
Profit Margin
-96.6%
Employees
57
BIAFW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $9.36M | $7.90M | $6.90M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.04M | $8.60M | $8.60M | -$6.33M |
| EPS (Diluted) | -$0.75 | -$0.91 | -$1.81 | $0.00 |
Total Assets
$6.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.11M
Operating Cash Flow
-$7.26M
Free Cash Flow
$0.00
bioAffinity Technologies Inc. Warrant Company Information
- Founder, President, CEO & Director
- Maria Zannes J.D.
- Headquarters
- 3300 Nacogdoches Road, San Antonio, TX, United States, 78217
- Website
- bioaffinitytech.com
- Phone
- 210 698 5334
- IPO / Founded
- 2022-09-01